How much data is building surrounding the many many parties surrounding PS Targeting IP leading to the discovery of new biomarkers and all those parties surrounding Avid CDMO?
One day we wake up to the realization that everyone wants a piece of knowledge out of Peregrine and ANY which way one can gain that knowledge ...most poach and pay up to give promotions, buy out patents, offer better jobs with big bonuses or other nefarious ways
Even Pfizer must not be left out of the loop, maybe Steve White can ask Dr Michael A White as Dr White has much PS Targeting knowledge from working with Dr Rolf Brekken and Dr John D Minna and it goes on and on....
Ronin Hedge Group brought one of the Best on board and Brian Weston that designed some of the best algos for trading platforms for BlackRock. He must be working overtime for Johnny S Stafford and Steve White at Ronin Capital, the activist shareholders at Avid CDMO have been awfully quiet
I can't imagine how frustrated they are after seeing a such stagnant share price...oops I keep forgetting about Brian Weston that Ronin has working for them. Ronin seems to follow Jim Cramer and never tell the truth I believe he said, and then no wonder why some tried to say IP assets were not worthy to hold onto, as Big Pharma likes all those that had any knowledge at all surrounding the IP of PS Targeting
____________
Brian Weston
Ronin Capital Greater Chicago Area Developing proprietary applications for Ronin Capital's traders and their operations team. .. ...
BlackRock 3 years 3 months Managing Director December 2009 – November 2011 2 years San Francisco, CA Managed the design, development, and deployment of the next generation equity order management system for the scientific active equity and index equity traders. The new OMS’s architecture was a real time, asynchronous, message based system with a proprietary distributed in-memory cache and with the primary servers located in three trading regions: San Francisco; London; and Tokyo. Installed in production on 5/03/2011 and was working well. The traders were ecstatic.
Mike White, Ph.D. VP/CSO, Tumor Cell Biology, Pfizer Inc. San Diego County, CA Pharmaceuticals161
Mike White, Ph.D.
VP/CSO, Tumor Cell Biology, Pfizer Inc. San Diego County, CA Pharmaceuticals 161
Summary
At Pfizer, our group pursues chemically addressable targets that intercept oncogenic signaling networks; modulate tumor/host interactions; and promote productive anti-tumor immune responses. We partner with colleagues in Medicinal Sciences, Drug Safety R&D, and Clinical Development to help deliver first-in-class small molecule drugs that benefit patient populations with unmet need.
Here at Pfizer, we participate in the ultimate transdisciplinary, multi-investigator, discovery and development campaign to deliver transformative therapies for patients that need them.
MICHAEL ANTHONY WHITE Vice President and Chief Scientific Officer, Tumor Cell Biology
I joined Pfizer in 2016 as CSO for Tumor Cell Biology, in the Oncology Research and Development Group. We are focused on the discovery and development of lead-in-class small molecule cancer therapies. Prior to Pfizer, I was Professor of Cell Biology; Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center; and inaugural Director of the Cancer Intervention and Prevention Discovery program at UT Southwestern Medical Center.
The research in my academic group over the past 20 years has helped define the nature of oncogenic cell regulatory networks; decode the molecular architecture of mitogenic signaling pathways; enrich functional annotation of cancer genomes; and deliver genomics-guided cancer intervention target nominations. This work has been described in ~150 publications with over 12,000 citations and an H-index of 65. (http://www.ncbi.nlm.nih.gov)
RESEARCH AREA(S) At Pfizer, our group pursues chemically addressable targets that intercept oncogenic signaling networks; modulate tumor/host interactions; and promote productive anti-tumor immune responses. We partner with colleagues in Medicinal Sciences, Drug Safety R&D, and Clinical Development to help deliver first-in-class small molecule drugs that benefit patient populations with unmet need.
PUBLICATIONS Mode of Action and Pharmacogenomic Biomarkers for Exceptional Responders to Didemnin B.Nature Chemical Biology. 2015; 11(6):401-8. Potts MB, McMillan EA, Rosales TI, Kim HS, Ou YH, Toombs JE, Brekken RA, Minden MD, MacMillan JB, White MA.https://www.ncbi.nlm.nih.gov/pubmed/25867045 XPO1-Dependent Nuclear Export is a Druggable Vulnerability in KRAS-Mutant Lung Cancer.Nature. 2016; 538(7623):114-117. Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. https://www.ncbi.nlm.nih.gov/pubmed/27680702 Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery. 2017; 7(8):832-851. Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA. https://www.ncbi.nlm.nih.gov/pubmed/28455392 Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nature Communications. 2017; 8(1):2270. Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Olswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA. https://www.ncbi.nlm.nih.gov/pubmed/29273768 Chemistry-First Approach for Nomination of Biomarker-Driven Intervention Opportunities in Lung Cancer. Cell. 2018. In Press. McMillan EA, Ryu M-J, Diep CH, Mendiratta S, Clemenceau JR, Vaden RM, Kim J-H, Motoyaji T, Covington KR, Peyton M, Huffman K, Wu X, Girard L, Sung Y, Chen P-H, Mallipedi PL, Lee JY, Hanson J, Yu Y, Park S, Sudderth J, DeSevo C, Muzny DM, Doddapaneni HV, Gazdar A, Gibbs RA, Hwang TH, Heymach JV, Wistuba I, Coombes KR, Williams NS, Wheeler DA, MacMillan JB, Deberardinis RJ, Roth MG, Posner BA, Minna JD, Kim HS, White MA. EDUCATION University of North Carolina, Chapel Hill, Biology, Ph.D., 1992 University of Iowa, Iowa City, Zoology, B.S., 1986
AWARDS & HONORS Hortense and Morton Sanger Professorship in Oncology, 2009 Sherry Wigley Crow Cancer Research Endowed Chair in Honor of R Kirby, M.D., 2009 – 2016 Grant A. Dove Distinguished Chair for Research in Oncology, 2011 – 2016 NCI Outstanding Investigator Award, 2015
